Bio-Techne Forms Partnership to Enhance Biotherapeutic Development
Bio-Techne and Waters Corporation Join Forces in Biotherapeutics
Bio-Techne Corporation (NASDAQ: TECH), a prominent player in biotherapeutic characterization, recently announced a strategic co-marketing and co-promotion agreement with Waters Corporation. This partnership aims to enhance the integration and efficiency of biotherapeutic development processes. By leveraging their respective strengths, they plan to deliver cutting-edge solutions that streamline workflows, ensuring precision while accelerating the path to market for vital therapies.
Innovative Technologies Combined
The collaboration will harness Bio-Techne's MauriceFlex™ System, which specializes in charge separation, alongside Waters' BioAccord™ LC-MS System for liquid chromatography mass spectrometry. These technologies, when integrated, will provide scientists with the tools necessary to conduct advanced characterization processes effectively. This synergy is expected to lead to innovative methodologies that not only optimize workflows but also enhance the accuracy of biotherapeutic analyses.
Joint Initiatives and Activities
In preparation for this collaboration, teams from both Bio-Techne and Waters participated in various joint initiatives aimed at sharing knowledge and building upon each company's expertise. Notably, they engaged in activities such as publishing educational materials, hosting webinars, and presenting scientific findings at prestigious conferences like CASSS MS and the Festival of Biologics. These events saw active participation from scientists and commercial representatives, all working together towards common goals.
Future Directions
As part of their ongoing efforts, application scientists from both companies are actively analyzing additional biomolecule classes. Findings from this research will be exhibited at future scientific conferences, ensuring continuous knowledge sharing within the community. This will further inform development materials like application notes, webinars, and presentations specifically tailored to highlight their advanced biotherapeutic characterization capabilities.
Bio-Techne's Vision and Commitment
“We are excited about the advancements these collaborative efforts are bringing to biopharma labs,” said Will Geist, President of the Protein Sciences Segment at Bio-Techne. “Our primary objective is to provide innovative solutions that help scientists streamline their workflows and expedite the delivery of life-saving therapies to market.” This commitment underlines Bio-Techne's dedication to the ongoing improvement of life science research and development.
About Bio-Techne Corporation
Bio-Techne Corporation (NASDAQ: TECH) operates as a leading global provider of innovative tools and bioactive reagents catering to the research and clinical diagnostic sectors. The breadth of Bio-Techne's product portfolio includes hundreds of thousands of items that support scientific investigation into various biological processes, disease progression, and drug discovery efforts. In the last fiscal year, Bio-Techne reported around $1.2 billion in net sales, sustaining its position as a leader in life sciences. With approximately 3,100 employees, Bio-Techne continues its mission to foster scientific advancement across the globe.
Frequently Asked Questions
What is the purpose of the Bio-Techne and Waters partnership?
The partnership aims to enhance biotherapeutic characterization and streamline development processes by combining the strengths of both companies.
What technologies are being utilized in this collaboration?
Bio-Techne's MauriceFlex™ System and Waters' BioAccord™ LC-MS System will be integrated to provide innovative solutions for biotherapeutic analysis.
What are the expected outcomes of these joint initiatives?
The collaboration is expected to result in improved workflows, greater precision in analyses, and faster timelines for bringing therapies to market.
Will there be educational materials available from this partnership?
Yes, the companies plan to produce application notes, conduct webinars, and present findings at scientific conferences as part of their collaborative efforts.
How does Bio-Techne support the life sciences community?
Bio-Techne provides various innovative tools and reagents that assist in research and diagnostics, facilitating scientific discoveries and advancements in health care.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.